INTENSITY THERAPEUTICS - Key Persons

Job Titles:

• Chairman
• Director
• Member of the Audit Committee
• Member of the Compensation Committee
• Member of the Nominating and Corporate Governance Committee
• Member of the Nominating and Corporate Governance Team

Daniel J. Donovan joined the Board in January 2023. Mr. Daniel Donovan is an entrepreneur with extensive experience within the biotech industry. Since 2014 to present he has been the Chief Executive Officer of rareLifeSolutions, Inc., a company creating the connections to engage, unify, and amplify the voices of patients, advocates, and caregivers to inform and accelerate the development and commercialization of emerging treatments especially in rare diseases. Dan was a member of the Board of Directors and Chief Business Officer at Cancer Prevention Pharmaceuticals (CPP), a late-stage pharmaceutical development company with compounds targeted at several rare diseases. Prior to rareLife and CPP, Dan established Envision Pharma in 2001, serving as President through June 2011. He was the visionary behind the creation and development of Datavision, the market leader in medical publications technology. Envision Pharma was acquired by the United BioSource Corporation (UBC) in April 2008. At UBC Mr. Daniel Donovan was Senior Vice President Strategy and Market Development. Dan began his career at Pfizer serving in a variety of positions of increasing responsibility, ranging from sales to market research and marketing in the US domestic and international market place, culminating in his position as Director and European Team Leader. During his time at Pfizer, he played a pivotal role in the commercialization of some of the pharmaceutical industry's most successful product launches. Dan earned a Bachelor of Science degree in Finance at Lehigh University. We believe that Mr. Daniel Donovan's background in cancer and rare disease, finance, drug development, patient advocacy and small company board experience allows him to make valuable contributions to our Board.

Job Titles:

• Member of the Senior Management Team
• Executive VP, Clinical Development
• Senior Vice President Clinical Development

Brian Schwartz, MD, joined our team as a consultant in... Brian Schwartz MD. Join our team as a consultant in April of 2022. He is our Executive Responsible for Clinical Development, Brian Schwartz MD, has significant experience in drug development in both the biotechnology and pharmaceutical industries. Dr. Schwartz most recently served as Chief Medical Officer and head of Research and Development of ArQule, Inc. where he served as a key member of the management team and spearheaded a number of preclinical and clinical drug development programs in oncology and rare diseases. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in the biopharmaceutical industry. Dr Schwartz currently serves as a board member a number of biotech companies.

Job Titles:

• Advisor
• Consultant

Intensity Therapeutics deeply regrets the passing of our longtime toxicology advisor Dr. Chris J. Viau, who passed away December 2021 after a long illness. Chris' technical skills were outstanding; his work effort, output and quality of the highest level. Without Chris our preclinical programs would never have been as robust. The world has lost an incredible scientist and he will be missed. We mourn for his wife of 42 years, Maureen (Twichell) Viau, and their daughters, Jessica Viau of Grafton, MA, and Allison Radler and her husband Jacob, of North Attleboro, MA. Chris was President of CJV Toxicology, LLC. Dr. Viau had over thirty-five years of applied technical, managerial and leadership expertise in toxicology, safety pharmacology, drug metabolism, pharmacokinetics, and product development across multiple therapeutic areas. He previously worked at Sunovion Pharmaceuticals and Hoechst-Marion Roussel (now Sanofi-Aventis).

Job Titles:

• Director
• Member of the Audit Committee
• Member of the Compensation Committee
• Audit

Dr. Emer Leahy has served on our board of directors since June 2016. Dr. Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. Since 2000, she has served as CEO of PsychoGenics Inc., a profitable preclinical CNS service company. She is also CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with five partnered clinical programs including one in Phase III. Further, she holds an Adjunct Associate Professor of Neuroscience position at Mount Sinai School of Medicine. Dr. Leahy has more than 30 years of experience in drug discovery, clinical development and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Dr. Leahy served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), the Business Review Board for the Alzheimer's Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She also currently serves on the Board of Directors of PsychoGenics Inc., Bright Minds Biosciences, Pasithea Therapeutics, and on the Board of Trustees of BIONJ.

Job Titles:

• Director
• Member of the Audit Committee
• Member of the Compensation Committee
• Member of the Nominating and Corporate Governance Committee
• Audit
• Senior Life Science Executive

Mark A. Goldberg, M.D. has served as a member of our board of directors since May 2018. Dr. Mark A. Goldberg recently served as President and COO of PAREXEL International, one of the world's largest global biopharmaceutical service providers, with consolidated service revenue of approximately $2.1 billion, over 18,000 employees, and 86 locations in 51 countries. He was responsible for overseeing all revenue generating business segments including Clinical Research Services, PAREXEL Informatics, and PAREXEL Consulting as well as sales, marketing, corporate quality, and information technology. Dr. Goldberg helped to pioneer PAREXEL's strategic partnering approach with some of the world's leading pharmaceutical companies and to build out the company's global infrastructure, particularly in the Asia Pacific region, through both organic growth and acquisitions. Earlier in his PAREXEL career, he founded the company's Medical Imaging business and helped establish its technology subsidiary, Perceptive Informatics (now PAREXEL Informatics). Dr. Goldberg holds a BS degree in computer science from MIT and an MD from the University of Massachusetts Medical School. He completed residency training in Radiology at Massachusetts General Hospital, where he also served as Chief Resident and a staff physician with academic appointments at Harvard Medical School. Dr. Mark A. Goldberg is a senior life science executive and innovator. Dr. Goldberg has served on the board of directors of Intensity Therapeutics, Inc. since 2017. Since 2018, he has served as Chairman and CEO of Allucent and Executive Chairman of THREAD. Prior to his current roles, Goldberg served as President and Chief Operating Officer at Parexel International, where he led one of the world's largest biopharmaceutical services companies. Goldberg was a key player on Parexel's executive management team for more than 20 years and served as Chief Operating Officer (and later President) for 10 years. He was instrumental in driving business results through the application of his combined medical, technical, and clinical research expertise. He oversaw the geographic expansion of Parexel's clinical development capabilities, including the extension of capabilities in the Asia-Pacific region. Before taking on the COO role, Goldberg served as President of Clinical Research Services, driving strong growth and performance in the company's largest business segment. Prior to that, he served as President of Perceptive Informatics (now Calyx), helping to build Parexel's leadership position in providing eClinical solutions that accelerate drug development. Before joining Parexel, Goldberg served as President and Director of WorldCare, Inc. (which he helped found), a telehealth spin-off from Massachusetts General Hospital (MGH). Goldberg holds a degree in computer science and engineering from the Massachusetts Institute of Technology and an M.D. from the University of Massachusetts Medical School. He completed residency training in diagnostic radiology at MGH, where he served as Chief Resident, as well as Staff Radiologist.

Dr. Riccardo Lencioni was most recently professor of clinical radiology at the University of Miami Miller School of Medicine and director of the Interventional Oncology Research Group. Previously Dr. Lencioni was professor and director of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Pisa, Italy. He is the founder of the International Liver Cancer Association (ILCA) and served as the ILCA executive secretary. Dr. Lencioni has also served as chairman of the World Conference of Interventional Oncology, a network of interventional oncologists dedicated to the development of treatment approaches based on imaging, such as intratumoral delivery. He has been involved in the development of recommendations for the research and clinical management of hepatocellular carcinoma, and co-authored the white papers, "Design and Endpoints in Clinical Trials in Hepatocellular Carcinoma" (2008), "Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma" (2010), and "EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma" (2012). Dr. Lencioni has published 190 articles in international peer-reviewed journals and 61 textbook chapters, and is the editor of nine books.

Job Titles:

• Executive Vice President
• Member of the Senior Management Team

James M. Ahlers has served as our Executive Vice President of Corporate Finance since June 2023. Previously, Mr. Ahlers served as our Chief Financial Officer from January 2022 until June 2023 through a consulting agreement with Mr. Ahlers' employer, Danforth Advisors LLC, a company that provides strategic and operational finance and accounting services to life science companies. From February 2002 to November 2019 Mr. Ahlers served as Chief Financial Officer of Intarcia Therapeutics, Inc. Mr. Ahlers is an accomplished finance leader with 25 years of experience building life science businesses. During his career, he has managed capital raising transactions, including initial public offerings, that have raised in excess of $2 billion. In addition, he has developed and implemented international operations and global tax strategies. Mr. Ahlers holds a B.S. in accounting from the University of San Francisco.

Dr. Berzofsky pioneered characterization of B- and T-cell epitopes and their modification to make epitope-enhanced vaccines, discovered the importance of T cell avidity in viral/tumor clearance, pioneered use of defined molecular adjuvants to alter quality of immune responses, advanced mucosal HIV vaccines, discovered NKT cell regulation of tumor immunity, and blocked negative regulation by TGF-beta, IL-13, and regulatory cells to enhance tumor immunity and vaccine efficacy. He translated these strategies to clinical trials in prostate cancer, melanoma, and HER2-positive cancers. As chief of the National Cancer Institute's Vaccine Branch, he oversees basic, translational, and clinical research in cancer and retroviral vaccines and immunotherapy.

Job Titles:

• Chief Financial Officer
• Interim Chief Financial Officer
• Member of the Senior Management Team

John Wesolowski has served as our Interim Chief Financial Officer since June 2023 and our Principal Accounting Officer and Controller since March 2017. Prior to joining Intensity Therapeutics, from 1998 to 2016 Mr. Wesolowski was Director of Costing in the Yale University Controller's office. In that role Mr. Wesolowski conducted financial reporting, property tax management, was responsible for calculations of overhead and benefit rates, and was involved in numerous special projects related to accounting process and controls. Also, at Yale, he was involved in financial reporting and the accounting matters related to clinical trials and other organized research. Prior to joining Yale Mr. Wesolowski was the Vice President and Controller for Automatic Fastener Corporation in Branford, CT from 1988 to 1998. In this role, Mr. Wesolowski oversaw all accounting, purchasing and human resource functions. John also has 5 years of experience in public accounting and auditing from working at KMG Main Hurdman, now KPMG. Mr. Wesolowski received a Bachelor of Science in Finance from The Pennsylvania State University (Penn State at University Park) and an MBA from the University of Connecticut in Management Science. He is a Certified Public Account since 1983.

Job Titles:

• CEO
• Chairman of the Board
• Founder
• Member of the Nominating and Corporate Governance Team
• Member of the Senior Management Team
• President

Lewis H. Bender is our founder and has served as our President and Chief Executive Officer since April 2012. Prior to our founding, Mr. Bender was the CEO of publicly traded (AMEX & OTC) Interleukin Genetics, Inc. from 2008 until 2012. Interleukin was a personalized medicine company. Mr. Bender was successful in raising capital for us via a direct placement with institutional investors and partnered with the insurance industry for development of an IG product. Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc. at the time a publicly traded (Nasdaq) drug delivery company specializing in the development of oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December 2007, Mr. Bender held positions including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. Mr. Bender has over 26 years of biotech and pharmaceutical executive management experience. He has led development teams taking products from discovery to Phase 3 for compounds using novel drug delivery techniques. Mr. Bender has a both a BS and MS in Chemical Engineering from The Massachusetts Institute of Technology (MIT), an MBA from the University of Pennsylvania's Wharton School, and an MA in International Studies also from the University of Pennsylvania. He is fluent in French and German. Mr. Bender has over 28 years of biopharmaceutical leadership experience and has helped take products leveraging novel drug delivery techniques from discovery through product approval. Prior to founding Intensity Therapeutics, Mr. Bender was the CEO of Interleukin Genetics, a personalized medicine company, from January 2008 until August 2012. Prior to joining Interleukin, Mr. Bender held numerous positions at Emisphere Technologies, Inc., a drug delivery company specializing in the oral delivery of poorly absorbed molecules. His roles included: Interim President & CEO, President, Chief Technology Officer, Senior Vice President of Business Development, and Senior Vice President of Manufacturing and Process Development. During his career, Mr. Bender has partnered with several major pharmaceutical and biotech companies using structures such as joint ventures, licensing and research collaboration agreements. In addition, Mr. Bender has been successful in raising capital from institutional investors through multiple types of transactions. Mr. Bender has a Bachelor of Science and a Master's of Science in Chemical Engineering from the Massachusetts Institute of Technology (MIT), a Masters of Business Administration (MBA) from the Wharton School of the University of Pennsylvania (UPenn) and a Masters of Arts in International Studies, also from UPenn.

Job Titles:

• Professor of Internal

Dr. Sznol is currently professor of internal medicine at Yale University School of Medicine, co-director of the Yale Melanoma Program, and co-director of Yale SPORE in Skin Cancer. He is an investigator in several clinical trials at the Yale Cancer Center, including those focusing on immunotherapy and novel agents. Dr. Sznol is an internationally recognized oncology drug developer, with expertise in cancer immunotherapy and the treatment of patients with melanoma and renal cell carcinoma. Dr. Sznol received his undergraduate degree from Rice University, trained in internal medicine at Baylor College of Medicine in Houston, Texas, and completed a medical oncology fellowship in the Department of Neoplastic Diseases at Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch of the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI), and was head of the BES from 1994-1999.

Job Titles:

• Rx Communications Group
• Rx Communications Group LLC

Job Titles:

• Member of the Senior Management Team
• Vice President
• Regulatory Affairs and Quality Control

Rebecca Drain served as our Vice President, Regulatory Affairs and Quality most recently and joined the company as Executive Director of Regulatory Affairs and Quality Assurance in July 2019. In August 2022 she became and currently serves as a consultant for the company. Prior to joining Intensity Therapeutics, Ms. Drain had nearly 25 years of experience with Bristol Myers Squibb, where most recently, between January 2015 and December 2018, she served as Director, Submission Management, Global Regulatory Safety and Biometrics, a position in which she was responsible for global oncology regulatory submissions. Prior to BMS, she was a research scientist with a drug discovery company. Ms. Drain earned a B.S. in Pathobiology from the University of Connecticut.